Sanofi - American Depositary Shares (NQ:SNY)

39.92 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

42 43 Next >

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

May 13, 2024

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

May 13, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Why Novavax Stock More Than Doubled Today ↗

May 10, 2024

A cloud of doubt hanging over the company just gave way to some sunshine.

Via The Motley Fool

NVAX Stock Alert: Novavax Just Hit a New 52-Week High ↗

May 10, 2024

Novavax stock is heading higher on Friday as NVAX investors celebrate it reaching a new 52-week high following a deal with Sanofi.

Via InvestorPlace

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗

April 29, 2024

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.

Via Benzinga

Topics Stocks

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? ↗

May 10, 2024

A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures.

Via Benzinga

Topics Economy

Novavax Sheds Going Concern Warning as NVAX Stock Pops on Sanofi Licensing Deal ↗

May 10, 2024

NVAX stock is rising higher after the biotechnology company announced that it had signed a licensing deal with Sanofi.

Via InvestorPlace

Biotech Rockets 125% On Sanofi Covid Vaccine Agreement ↗

May 10, 2024

Novavax will receive as much as $1.2 billion as part of a Covid vaccine licensing deal with Sanofi.

Via Investor's Business Daily

Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern ↗

May 10, 2024

Novavax strikes co-exclusive licensing deal with Sanofi (SNY) for COVID-19 and flu-COVID-19 vaccines. Terms include upfront payment of $500M, milestone opportunities, and revenue guidance update.

Via Benzinga

Why Is Novavax (NVAX) Stock Up 118% Today? ↗

May 10, 2024

Novavax stock is up on Friday after the vaccine company announced a licensing agreement with Sanofi as its Q1 earnings report.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

May 10, 2024

The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning!

Via InvestorPlace

3 Biotech Stocks to Sell in May Before They Crash & Burn ↗

May 10, 2024

Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.

Via InvestorPlace

The 3 Most Undervalued Pharma Stocks to Buy in May 2024 ↗

May 09, 2024

Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks.

Via InvestorPlace

Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac ↗

May 08, 2024

Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing.

Via Benzinga

Topics Lawsuit

Sanofi's New Cancer Drug Could Help Deliver a Big Payday ↗

May 08, 2024

Investors should expect a modest 2024 before seeing more exciting returns for the drugmaker in 2025 following the expected approval of rilzabrutinib.

Via The Motley Fool

Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation ↗

May 02, 2024

Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.

Via Benzinga

3 Biotech Stocks to Buy and Hold Through 2030 and Beyond ↗

May 02, 2024

It pays to develop novel medicines for life-threatening illnesses.

Via The Motley Fool

The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024

April 30, 2024

From Pinnacle Group International

Via ACN Newswire

Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates ↗

April 28, 2024

The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for...

Via Talk Markets

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study ↗

April 25, 2024

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.

Via Benzinga

Sanofi (SNY) Q1 2024 Earnings Call Transcript ↗

April 25, 2024

SNY earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday ↗

April 25, 2024

Via Benzinga

Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings ↗

April 25, 2024

Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to...

Via Benzinga

SNY Stock Earnings: Sanofi Beats EPS, Beats Revenue for Q1 2024 ↗

April 25, 2024

SNY stock results show that Sanofi beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags ↗

April 25, 2024

AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

Via Investor's Business Daily

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick ↗

April 17, 2024

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...

Via Benzinga

Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years ↗

April 17, 2024

Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed.

Via Benzinga

US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst ↗

April 25, 2024

The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META)

Via Benzinga

Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity ↗

April 17, 2024

Discover results from Sanofi's Phase 2 study on frexalimab for relapsing multiple sclerosis. Explore sustained reduction in disease activity and lesion numbers with low relapse rates.

Via Benzinga

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗

April 21, 2024

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.